Alexander J. Denner
Alexander J. Denner's purchase track record
How the stock did after each of Alexander J. Denner's open-market purchases, measured from the purchase date. Several fills within a week count as one purchase.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 6/15/2023 | INVA | $814K | -3.0% | +16.8% | +6.6% |
| 6/5/2023 | INVA | $196K | -4.7% | +9.0% | +6.9% |
| 5/25/2023 | INVA | $2.61M | +1.1% | +5.8% | +9.8% |
| 5/11/2023 | INVA | $4.36M | +9.5% | +8.5% | +5.3% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Innoviva (INVA) Draws Value Investor Attention Amid Low Valuation. Recent articles highlight Innoviva's low price-to-earnings ratio of 4.3, positioning it as a potential value pick compared to peers like Merck. With the stock trading near its 52-week low, analysts are debating whether the current price reflects undervaluation or persistent risk. The focus on valuation metrics suggests investors are scrutinizing the company's financial appeal rather than recent operational news.
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Biogen sees kidney therapy progress and rating upgrade. Biogen is receiving attention after a kidney transplant milestone was reported, highlighting its involvement in kidney disease research. The company’s partner Estuary Therapeutics raised $93 million to advance a gene‑therapy for kidney disease, adding to the pipeline focus. Analysts have upgraded Biogen’s outlook, noting growth potential beyond its Alzheimer’s products. An earnings preview also points to upcoming results that could shape market views.
Transaction History
| IRWD | ▲ Buy | Grant | 3,694 | $0 | 9/15/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 63,481 | $0 | 6/16/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 4,065 | $0 | 6/15/2026 | View on chart |
| IRWD | ▼ Sell | Open Market | 6,725,000 | $20.5M | 3/17/2026 | View on chart |
| IRWD | ▼ Sell | Open Market | 5,800 | $19K | 3/17/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 4,451 | $0 | 3/13/2026 | View on chart |
| IRWD | ▲ Buy | Grant | 4,178 | $0 | 12/15/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 11,718 | $0 | 9/15/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 24,193 | $0 | 6/13/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 45,000 | $0 | 6/10/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 10,416 | $0 | 4/2/2025 | View on chart |
| INVA | ▼ Sell | Open Market | 1,196,746 | $21.0M | 3/6/2025 | View on chart |
| INVA | ▼ Sell | Open Market | 270,374 | $4.8M | 3/5/2025 | View on chart |
| INVA | ▼ Sell | Open Market | 151,175 | $2.7M | 3/4/2025 | View on chart |
| IRWD | ▲ Buy | Grant | 4,249 | $0 | 12/16/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 3,282 | $0 | 9/16/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 24,311 | $0 | 6/18/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 2,572 | $0 | 6/15/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 1,662 | $0 | 3/15/2024 | View on chart |
| IRWD | ▲ Buy | Grant | 1,347 | $0 | 12/15/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 1,798 | $0 | 9/15/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 22,350 | $0 | 6/20/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 62,000 | $814K | 6/15/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 1,359 | $0 | 6/15/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 8,000 | $104K | 6/6/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 7,000 | $91K | 6/5/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 120,000 | $1.6M | 5/30/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 30,000 | $394K | 5/26/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 50,000 | $654K | 5/25/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 10,000 | $131K | 5/18/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 50,000 | $654K | 5/17/2023 | View on chart |
| INVA | ▲ Buy | Open Market | 290,000 | $3.6M | 5/11/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 1,438 | $0 | 3/15/2023 | View on chart |
| IRWD | ▲ Buy | Grant | 1,244 | $0 | 12/15/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 1,374 | $0 | 9/15/2022 | View on chart |
| BIIB | ▲ Buy | Grant | 1,370 | $0 | 6/15/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 1,222 | $0 | 6/15/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 21,571 | $0 | 6/1/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 1,152 | $0 | 3/15/2022 | View on chart |
| IRWD | ▲ Buy | Grant | 1,211 | $0 | 12/15/2021 | View on chart |
| IRWD | ▲ Buy | Grant | 1,137 | $0 | 9/15/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 16, 2026
Ironwood Pharmaceuticals names Tammi Gaskins as CEO
Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.
Ironwood Pharmaceuticals names Tammi Gaskins as CEO. Ironwood Pharmaceuticals announced that Tammi Gaskins will become chief executive officer on Jan. 1, 2027. The leadership change comes as the stock is trading near a long‑standing support level around $4.04. The appointment adds a fresh perspective to Ironwood’s management team and may be relevant to its ongoing operations and pipeline.